Detalhe da pesquisa
1.
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Lancet
; 401(10378): 747-761, 2023 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36746171
2.
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
Br J Dermatol
; 186(6): 942-954, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34981829
3.
A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results.
J Am Acad Dermatol
; 86(1): 122-130, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34555481
4.
Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial.
Dermatol Ther
; 35(3): e15285, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34954841
5.
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
Acta Derm Venereol
; 102: adv00698, 2022 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35146532
6.
Dose-dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity.
Diabetes Obes Metab
; 22(7): 1102-1110, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32072763
7.
Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure.
Br J Clin Pharmacol
; 86(7): 1346-1356, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32068914
8.
Assessing the validity and clinical meaningfulness of skin pain response (NRS30) assessed using numerical rating scale in hidradenitis suppurativa: Results from the SUNSHINE and SUNRISE trials.
J Am Acad Dermatol
; 89(6): 1285-1287, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37579844
9.
Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials.
Am J Clin Dermatol
; 24(5): 821-835, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37341961
10.
Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study.
Paediatr Drugs
; 24(4): 377-387, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35698000
11.
Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study.
J Dermatolog Treat
; 33(3): 1718-1726, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33896356
12.
Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity.
Obesity (Silver Spring)
; 28(5): 870-881, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32187881
13.
Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial.
J Hypertens
; 26(3): 589-99, 2008 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-18300872
14.
Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy.
J Clin Hypertens (Greenwich)
; 9(10): 742-50, 2007 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17917501
15.
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
J Clin Oncol
; 23(31): 7811-9, 2005 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16258083
16.
Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension.
Hypertens Res
; 29(12): 997-1005, 2006 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17378372
17.
Cardiac dysfunction in the trastuzumab clinical trials experience.
J Clin Oncol
; 20(5): 1215-21, 2002 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-11870163
18.
QTc interval prolongation associated with intravenous methadone.
Pain
; 105(3): 499-506, 2003 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-14527710
19.
Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer.
Clin Breast Cancer
; 5(4): 293-8, 2004 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-15507176
20.
Pharmacokinetics, safety profile, and efficacy of aliskiren in pediatric patients with hypertension.
Clin Pediatr (Phila)
; 52(7): 599-607, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23610239